	US 11,744,829 B2
	Methods for treating neurological conditions and exposure to nerve agents
Maria F. Braga, Bethesda, MD (US); and Vassiliki Aroniadou-Anderjaska, Bethesda, MD (US)
Assigned to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US)
Filed by The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US)
Filed on Jun. 28, 2021, as Appl. No. 17/360,912.
Application 17/360,912 is a continuation of application No. 16/309,898, granted, now 11,045,462, previously published as PCT/US2017/036816, filed on Jun. 9, 2017.
Claims priority of provisional application 62/349,819, filed on Jun. 14, 2016.
Prior Publication US 2021/0393615 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/215 (2006.01); A61K 31/472 (2006.01); A61K 31/551 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 39/02 (2006.01); A61K 31/4725 (2006.01); A61K 31/015 (2006.01); A61K 31/216 (2006.01); A61K 31/41 (2006.01); A61K 31/5517 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/4725 (2013.01) [A61K 31/015 (2013.01); A61K 31/216 (2013.01); A61K 31/41 (2013.01); A61K 31/5517 (2013.01); A61K 45/06 (2013.01)]

17 Claims

1. A method of treating or reducing the toxic effects of exposure to a nerve agent, or treating or reducing the risks of a neurological condition, comprising administering to a mammalian subject in need thereof:

(i) an AMPA/GluR5(GluK1) kainate receptor antagonist and

(ii) an NMDA receptor antagonist, and, optionally, further comprising administering a positive allosteric modulator of synaptic GABA_Areceptors to the subject,

wherein the AMPA/GluR5(GluK1) kainate receptor antagonist and the NMDA receptor antagonist and, optionally, the positive allosteric modulator of synaptic GABA.sub.A receptors, are administered orally or via a route of injection selected from intravenous, subcutaneous, and intraperitoneal.